Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choline alfoscerate added to transdermal rivastigmine in Alzheimer's disease with severe behavioral disturbances
2009-016955-23Phase 2Terminated
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- Jun 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of choline alfoscerate and rivastigmine in Alzheimer's disease (AD), sponsored by Azienda USL Toscana Nord Ovest. Primary endpoints: Dementia progression and Behavioral disturbances. Started Jun 2010; status: terminated.
02
Drugs
choline alfosceraterivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-016955-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016955-23.